Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free VTVT Stock Alerts

vTv Therapeutics (VTVT) Financials

vTv Therapeutics logo
$30.73 -0.93 (-2.94%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$30.70 -0.03 (-0.10%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for vTv Therapeutics

Annual Income Statements for vTv Therapeutics

This table shows vTv Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -36 -27 -72 -16 -7.91 -13 -8.50 -13 -19 -20 -18
Consolidated Net Income / (Loss)		 -36 -41 -55 -55 -24 -22 -13 -18 -25 -26 -23
Net Income / (Loss) Continuing Operations		 -36 -41 -55 -55 -24 -22 -13 -18 -25 -26 -23
Total Pre-Tax Income 		-36 -41 -55 -54 -24 -22 -13 -18 -25 -26 -23
Total Operating Income		 -29 -38 -55 -51 -20 -21 -12 -22 -23 -26 -24
Total Gross Profit		 1.55 0.52 0.63 0.29 12 2.76 6.41 4.01 2.02 0.00 1.02
Total Revenue		 1.55 0.52 0.63 0.29 12 2.76 6.41 4.01 2.02 0.00 1.02
Operating Revenue		 1.55 0.52 0.63 0.29 12 2.76 6.41 4.01 2.02 0.00 1.02
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 30 39 56 51 32 24 18 26 25 26 25
Selling, General & Admin Expense		 12 9.08 9.91 11 9.22 8.54 7.25 12 12 12 14
Research & Development Expense		 19 30 46 40 23 15 11 13 12 14 12
Total Other Income / (Expense), net		 -7.20 -2.97 -0.33 -3.17 -3.82 -0.95 -0.95 4.05 -2.33 -0.46 1.58
Interest Expense		 6.01 1.78 0.40 3.09 3.29 1.83 0.69 0.01 0.02 0.01 0.00
Interest & Investment Income		 -0.07 0.04 0.09 0.12 0.06 0.05 0.01 0.00 0.35 0.47 1.57
Other Income / (Expense), net		 -1.13 -1.23 -0.02 -0.19 -0.59 0.83 -0.27 4.06 -2.67 -0.92 0.01
Income Tax Expense		 0.00 0.00 0.00 0.80 0.20 0.10 0.00 0.12 0.20 0.00 0.10
Net Income / (Loss) Attributable to Noncontrolling Interest		 - -14 -39 -39 -16 -8.89 -4.30 -4.74 -5.91 -5.72 -4.24
Basic Earnings per Share		 - - - ($1.67) ($0.69) ($0.59) ($0.18) ($8.29) ($9.98) ($9.71) ($3.20)
Weighted Average Basic Shares Outstanding		 - 8.28M 9.55M 9.69M 12.45M 0.00 47.14M 1.57M 1.92M 2.08M 5.77M
Diluted Earnings per Share		 - - - ($1.67) ($0.69) ($0.59) ($0.18) ($8.29) ($9.98) ($9.71) ($3.20)
Weighted Average Diluted Shares Outstanding		 - 8.28M 9.55M 9.69M 12.45M 0.00 47.14M 1.57M 1.92M 2.08M 5.77M
Weighted Average Basic & Diluted Shares Outstanding		 - 8.28M 9.55M 9.69M 12.45M 30.29M 0.00 0.00 104.58M 3.01M 3.19M

Quarterly Income Statements for vTv Therapeutics

This table shows vTv Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -6.65 -3.48 -4.87 -5.18 -4.78 -3.63 -5.09 -6.05 -8.70 24
Consolidated Net Income / (Loss)		 -8.54 -4.44 -6.02 -6.41 -5.84 -4.44 -6.22 -7.38 -10 24
Net Income / (Loss) Continuing Operations		 -8.54 -4.44 -6.02 -6.41 -5.84 -4.44 -6.22 -7.38 -10 24
Total Pre-Tax Income 		-8.54 -4.44 -5.92 -6.41 -5.84 -4.44 -6.22 -7.38 -10 24
Total Operating Income		 -5.37 -4.71 -5.63 -7.16 -6.51 -4.89 -6.50 -7.72 -11 23
Total Gross Profit		 0.00 - 1.00 0.00 0.00 0.02 0.00 0.00 0.00 37
Total Revenue		 0.00 - 1.00 0.00 0.00 0.02 0.00 0.00 0.00 37
Operating Revenue		 0.00 - 1.00 0.00 0.00 0.02 0.00 0.00 0.00 37
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Operating Expenses		 5.37 4.71 6.63 7.16 6.51 4.91 6.50 7.72 11 14
Selling, General & Admin Expense		 2.54 2.57 3.98 3.72 3.28 2.68 3.67 3.62 3.68 4.60
Research & Development Expense		 2.82 2.14 2.65 3.44 3.22 2.23 2.83 4.10 7.02 8.98
Total Other Income / (Expense), net		 -3.17 0.27 -0.29 0.75 0.67 0.46 0.29 0.34 0.35 0.87
Interest & Investment Income		 0.13 0.09 0.08 0.55 0.50 0.43 0.33 0.28 0.40 0.84
Other Income / (Expense), net		 -3.30 0.19 -0.37 0.19 0.16 0.03 -0.05 0.07 -0.04 0.03
Income Tax Expense		 0.00 - 0.10 0.00 0.00 - 0.00 0.00 0.00 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest		 -1.89 -0.96 -1.15 -1.23 -1.06 -0.80 -1.13 -1.33 -1.65 0.00
Basic Earnings per Share		 ($3.19) ($1.67) ($1.17) ($0.81) ($0.88) ($0.63) ($0.77) ($0.92) ($1.08) $1.94
Weighted Average Basic Shares Outstanding		 2.08M 2.08M 4.14M 6.40M 5.46M 5.77M 6.58M 6.59M 8.06M 12.41M
Diluted Earnings per Share		 ($3.19) ($1.67) ($1.17) ($0.81) ($0.88) ($0.63) ($0.77) ($0.92) ($1.08) $1.65
Weighted Average Diluted Shares Outstanding		 2.08M 2.08M 4.14M 6.40M 5.46M 5.77M 6.58M 6.59M 8.06M 14.63M
Weighted Average Basic & Diluted Shares Outstanding		 104.58M 3.01M 3.01M 3.01M 3.19M 3.19M 3.19M 3.19M 3.94M 3.94M

Annual Cash Flow Statements for vTv Therapeutics

This table details how cash moves in and out of vTv Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 0.30 87 -36 -37 -10 0.09 1.47 7.67 -1.29 -2.68 27
Net Cash From Operating Activities		 -31 -37 -48 -45 -27 -23 -18 -19 -16 -19 -25
Net Cash From Continuing Operating Activities		 -31 -37 -48 -45 -27 -23 -18 -19 -16 -19 -25
Net Income / (Loss) Continuing Operations		 -36 -41 -55 -55 -24 -22 -13 -18 -25 -26 -23
Consolidated Net Income / (Loss)		 -36 -41 -55 -55 -24 -22 -13 -18 -25 -26 -23
Depreciation Expense		 0.86 0.50 0.27 0.20 0.22 0.04 0.09 0.09 0.09 0.09 0.09
Non-Cash Adjustments To Reconcile Net Income		 0.95 1.58 2.69 3.82 -7.13 0.40 -4.48 -2.71 10 2.40 2.75
Changes in Operating Assets and Liabilities, net		 -1.41 2.05 4.04 5.04 2.89 -2.05 -1.19 1.04 -1.38 4.39 -5.44
Net Cash From Investing Activities		 0.16 -0.08 -0.08 -0.03 0.01 0.24 0.00 0.00 -0.02 4.40 0.00
Net Cash From Continuing Investing Activities		 0.16 -0.08 -0.08 -0.03 0.01 0.24 0.00 0.00 -0.02 4.40 0.00
Purchase of Property, Plant & Equipment		 -0.03 -0.10 -0.09 -0.06 -0.01 -0.07 0.00 0.00 -0.02 0.00 0.00
Sale and/or Maturity of Investments		 - - - - - - - 0.00 0.00 4.40 0.00
Net Cash From Financing Activities		 31 124 12 7.50 17 23 19 27 15 12 53
Net Cash From Continuing Financing Activities		 31 124 12 7.50 17 23 19 27 15 12 53
Repayment of Debt		 -0.15 -0.09 -0.71 - -5.39 -11 -5.46 -0.72 -0.81 -0.60 -0.19
Issuance of Debt		 34 19 13 7.50 0.50 0.50 0.50 0.89 0.78 0.57 0.00
Issuance of Common Equity		 - 106 - - 22 33 24 27 0.00 0.00 53
Other Financing Activities, net		 - -1.33 - - - 0.00 0.00 0.05 15 12 0.00
Cash Interest Paid		 0.14 0.08 0.24 2.06 2.28 1.30 0.62 0.01 0.02 0.01 0.00
Cash Income Taxes Paid		 - - - - 1.00 0.10 0.00 0.12 0.20 0.00 0.10

Quarterly Cash Flow Statements for vTv Therapeutics

This table details how cash moves in and out of vTv Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Net Change in Cash & Equivalents		 -4.36 1.21 43 -6.73 -3.96 -4.83 -5.69 -5.14 73 9.15
Net Cash From Operating Activities		 -4.83 -2.91 -7.34 -6.73 -6.42 -4.83 -5.69 -5.10 -5.22 9.15
Net Cash From Continuing Operating Activities		 -4.83 -2.91 -7.34 -6.73 -6.42 -4.83 -5.69 -5.10 -5.22 9.15
Net Income / (Loss) Continuing Operations		 -8.54 -4.44 -6.02 -6.41 -5.84 -4.44 -6.22 -7.38 -10 24
Consolidated Net Income / (Loss)		 -8.54 -4.44 -6.02 -6.41 -5.84 -4.44 -6.22 -7.38 -10 24
Depreciation Expense		 0.02 0.02 0.02 0.02 0.02 0.02 0.01 0.00 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income		 3.73 0.22 0.59 0.67 0.69 0.80 0.86 0.86 1.05 -15
Changes in Operating Assets and Liabilities, net		 -0.05 1.29 -1.93 -1.01 -1.29 -1.21 -0.34 1.42 4.07 0.50
Net Cash From Investing Activities		 - 4.40 0.00 - - - 0.00 - - 0.00
Net Cash From Continuing Investing Activities		 - 4.40 0.00 - - - 0.00 - - 0.00
Net Cash From Financing Activities		 0.47 -0.28 50 - 2.46 - 0.00 -0.04 78 0.00
Net Cash From Continuing Financing Activities		 0.47 -0.28 50 - 2.46 - 0.00 -0.04 78 0.00

Annual Balance Sheets for vTv Therapeutics

This table presents vTv Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 92 54 28 8.56 9.27 15 25 33 11 38 90
Total Current Assets		 89 52 20 3.47 2.84 7.22 16 27 11 38 90
Cash & Equivalents		 88 52 12 1.68 1.78 5.75 13 12 9.45 37 89
Prepaid Expenses		 1.11 0.61 0.44 0.67 0.81 0.94 2.05 2.54 1.04 1.19 0.74
Other Current Assets		 - - - 1.12 0.25 0.37 0.10 0.02 0.07 0.18 0.22
Plant, Property, & Equipment, net		 0.62 0.44 0.28 0.07 0.46 0.37 0.28 0.21 0.12 0.03 0.00
Total Noncurrent Assets		 1.72 1.93 7.27 5.02 5.97 7.21 9.58 5.94 0.24 0.13 0.01
Other Noncurrent Operating Assets		 1.72 1.93 2.29 0.04 0.99 0.48 0.40 0.35 0.24 0.13 0.01
Total Liabilities & Shareholders' Equity		 92 54 28 8.56 9.27 15 25 33 11 38 90
Total Liabilities		 7.97 23 48 29 18 11 10 27 30 24 25
Total Current Liabilities		 7.73 11 27 19 13 6.39 8.50 7.71 11 5.20 6.64
Accounts Payable		 7.51 11 14 7.70 7.07 6.12 8.02 7.31 10 5.03 6.56
Other Current Liabilities		 - - - - 0.11 0.16 0.18 0.15 0.17 0.17 0.08
Total Noncurrent Liabilities		 0.25 11 21 10 4.73 4.61 1.75 20 19 19 19
Noncurrent Deferred Revenue		 - - 4.50 1.07 1.03 1.01 0.00 19 19 19 19
Other Noncurrent Operating Liabilities		 0.25 0.43 0.29 0.26 1.09 0.73 0.49 1.02 0.28 0.10 0.15
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -78 -91 -151 -83 -49 -80 -9.74 -11 -25 14 64
Total Preferred & Common Equity		 -78 -91 -151 -83 -49 -80 -9.74 -11 -25 12 64
Total Common Equity		 -78 -91 -151 -83 -49 -80 -9.74 -11 -25 12 64
Common Stock		 118 124 128 151 184 210 239 255 256 312 391
Retained Earnings		 -196 -215 -279 -234 -234 -290 -249 -266 -281 -300 -327

Quarterly Balance Sheets for vTv Therapeutics

This table presents vTv Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 15 54 46 43 32 26 99 99
Total Current Assets		 10 54 46 43 32 26 99 99
Cash & Equivalents		 8.24 52 46 42 31 26 99 98
Prepaid Expenses		 1.87 0.57 0.30 1.06 0.74 0.36 0.84 0.52
Other Current Assets		 0.02 0.07 0.07 0.09 0.12 0.09 0.11 0.20
Plant, Property, & Equipment, net		 0.14 0.10 0.07 0.05 0.02 0.02 0.01 0.00
Total Noncurrent Assets		 4.66 0.22 0.19 0.16 0.09 0.06 0.02 0.01
Other Noncurrent Operating Assets		 0.27 0.22 0.19 0.16 0.09 0.06 0.02 0.01
Total Liabilities & Shareholders' Equity		 15 54 46 43 32 26 99 99
Total Liabilities		 29 28 26 25 23 24 29 8.85
Total Current Liabilities		 10 8.92 6.99 6.42 4.32 5.30 10 6.88
Accounts Payable		 9.62 8.73 6.79 6.23 4.19 5.22 9.80 6.82
Other Current Liabilities		 0.17 0.17 0.18 0.18 0.13 0.08 0.03 0.06
Total Noncurrent Liabilities		 19 19 19 19 19 19 19 1.97
Noncurrent Deferred Revenue		 19 19 19 19 19 19 19 1.83
Other Noncurrent Operating Liabilities		 0.49 0.61 0.37 0.16 0.15 0.08 0.12 0.14
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -25 26 20 18 8.90 2.41 71 90
Total Preferred & Common Equity		 -25 21 16 15 7.92 2.76 71 90
Total Common Equity		 -25 21 16 15 7.92 2.76 71 90
Common Stock		 256 307 308 311 313 314 390 393
Retained Earnings		 -281 -286 -291 -296 -305 -311 -320 -303

Annual Metrics And Ratios for vTv Therapeutics

This table displays calculated financial ratios and metrics derived from vTv Therapeutics' official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
DEI Shares Outstanding		 0.00 32,812,500.00 32,812,500.00 32,812,500.00 40,746,369.00 59,903,154.00 73,880,351.00 90,036,637.00 104,577,460.00 104,577,460.00 3,189,606.00
DEI Adjusted Shares Outstanding		 0.00 820,313.00 820,313.00 820,313.00 1,018,659.00 1,497,579.00 1,847,009.00 2,250,916.00 2,614,437.00 2,614,437.00 3,189,606.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -33.52 -87.41 -19.68 -7.77 -8.71 -4.60 -5.77 -7.33 -7.75 -5.79
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 58.71% -66.49% 22.16% -54.10% 4,172.85% -77.77% 132.06% -37.56% -49.61% -100.00% 0.00%
EBITDA Growth		 2.29% -60.24% -40.62% 9.11% 61.36% -1.61% 40.25% -50.38% -43.40% -4.85% 8.56%
EBIT Growth		 17.44% -31.14% -39.80% 7.58% 59.87% 1.72% 39.58% -45.23% -43.20% -4.82% 8.53%
NOPAT Growth		 19.36% -31.99% -44.25% 7.88% 60.89% -5.39% 43.27% -82.77% -4.05% -13.14% 5.18%
Net Income Growth		 25.11% -13.87% -34.66% 1.28% 56.37% 8.00% 41.64% -38.50% -41.41% -3.56% 12.56%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 58.68% 14.49% 69.49% -38.50% -41.41% 2.71% 67.04%
Operating Cash Flow Growth		 26.16% -20.04% -30.49% 7.57% 39.73% 14.29% 21.80% -7.27% 17.02% -19.09% -32.63%
Free Cash Flow Firm Growth		 0.00% -927.85% 29.48% 18.05% 23.30% 22.10% 43.68% -60.05% 33.67% 82.97% -1,212.12%
Invested Capital Growth		 0.00% 82.96% -99.84% -85.06% 45.92% 23.20% 16.12% -2.17% -99.23% -138.64% 19.27%
Revenue Q/Q Growth		 0.00% 0.00% -22.87% 203.13% 0.00% 0.00% 29,054.55% -61.47% 0.00% -100.00% 1.70%
EBITDA Q/Q Growth		 0.00% 0.00% -4.19% 2.70% 38.15% -36.77% 41.46% -175.19% 11.43% 6.11% -1.45%
EBIT Q/Q Growth		 0.00% 0.00% -4.28% 0.69% 36.68% -33.30% 40.60% -172.78% 11.39% 6.09% -1.44%
NOPAT Q/Q Growth		 0.00% 0.00% -4.21% 1.06% 38.52% -40.64% 40.95% -148.33% 17.45% 6.03% -0.77%
Net Income Q/Q Growth		 0.00% 0.00% -5.03% -1.64% 0.00% 0.00% 39.87% -166.99% 11.92% 5.97% 0.02%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 32.95% 25.00% -166.99% 11.92% 5.91% 4.76%
Operating Cash Flow Q/Q Growth		 0.00% -5.70% -5.37% 10.26% 1.69% -0.03% 16.91% -27.84% -2.98% 17.21% -8.17%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 22.18% -38.47% 7.34% 39.99% -67.74% -6.71% 59.98% -12.54%
Invested Capital Q/Q Growth		 0.00% 0.00% -24.14% -130.76% 37.53% -3.18% -14.39% -172.76% 2.17% -4.28% 5.13%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 100.00%
EBITDA Margin		 -1,564.95% -7,484.39% -8,615.62% -17,060.48% -154.29% -705.25% -181.60% -437.35% -1,244.70% 0.00% -2,367.85%
Operating Margin		 -1,865.53% -7,349.13% -8,678.23% -17,416.49% -159.43% -755.86% -184.78% -540.87% -1,116.95% 0.00% -2,377.58%
EBIT Margin		 -1,938.22% -7,586.13% -8,681.70% -17,481.79% -164.19% -725.90% -188.99% -439.58% -1,249.26% 0.00% -2,376.60%
Profit (Net Income) Margin		 -2,330.60% -7,920.42% -8,730.76% -18,779.04% -191.77% -793.70% -199.59% -442.72% -1,242.47% 0.00% -2,232.55%
Tax Burden Percent		 100.00% 100.00% 100.00% 101.49% 100.85% 100.46% 100.00% 100.65% 100.80% 100.00% 100.44%
Interest Burden Percent		 120.24% 104.41% 100.57% 105.85% 115.82% 108.84% 105.61% 100.06% 98.66% 98.26% 93.53%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 59.45% -359.94% -96.16% -913.60% 119.29% 150.20% 507.31% -186.49% -238.10% 408.59% 1,068.97%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -231.82% -75.37% -75.39% -123.46% -111.94% -225.12% -100.79% -87.45% -85.88% 0.00% -98.08%
Return on Assets (ROA)		 -278.75% -78.69% -75.81% -132.62% -130.74% -246.15% -106.44% -88.08% -85.41% 0.00% -92.14%
Return on Common Equity (ROCE)		 488.41% 9,094.32% 141.63% 18,530.90% 698.92% 678.11% 12,979.31% 881.15% 231.53% 1,138.66% 3,140.74%
Return on Equity Simple (ROE_SIMPLE)		 7.24% 52.72% 60.86% 36.18% 28.78% 44.75% 15.98% 182.04% 233.45% 105.21% -186.12%
Net Operating Profit after Tax (NOPAT)		 -20 -27 -39 -35 -14 -15 -8.30 -15 -16 -18 -17
NOPAT Margin		 -1,305.87% -5,144.39% -6,074.76% -12,191.55% -111.60% -529.10% -129.35% -378.61% -781.86% 0.00% -1,664.31%
Net Nonoperating Expense Percent (NNEP)		 91.61% -54.01% -26.22% -102.87% 135.95% 108.33% -120.13% -16.79% -48.21% -60.68% -25.13%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - 150.04% 72.90% -118.36%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 756.42% 1,748.94% 1,562.46% 3,894.50% 74.18% 308.86% 113.05% 308.19% 604.61% 0.00% 1,342.28%
R&D to Revenue		 1,209.10% 5,700.19% 7,215.77% 13,621.99% 185.26% 547.00% 171.73% 332.68% 612.34% 0.00% 1,135.30%
Operating Expenses to Revenue		 1,965.53% 7,449.13% 8,778.23% 17,516.49% 259.43% 855.86% 284.78% 640.87% 1,216.95% 0.00% 2,477.58%
Earnings before Interest and Taxes (EBIT)		 -30 -39 -55 -51 -20 -20 -12 -18 -25 -26 -24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -24 -39 -55 -50 -19 -19 -12 -18 -25 -26 -24
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.61
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.61
Price to Revenue (P/Rev)		 0.00 430.55 249.98 677.67 8.68 36.84 21.42 22.37 34.35 0.00 43.31
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 572.22 379.42 1,147.18 14.64 52.07 32.57 23.03 33.90 0.00 9.24
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -0.60 0.00 0.35 -1.00 -0.77 -0.70 0.02 0.02 0.04 -0.01 0.00
Long-Term Debt to Equity		 -0.59 0.00 0.35 -0.78 -0.31 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.57 -2.34 -1.12 -3.12 -0.37 -0.46 1.49 -1.61 -1.83 2.10 10.83
Leverage Ratio		 -0.21 4.57 1.27 6.89 -0.91 -0.61 -4.77 2.12 2.79 -3.48 -11.60
Compound Leverage Factor		 -0.26 4.78 1.28 7.29 -1.06 -0.66 -5.03 2.12 2.75 -3.42 -10.85
Debt to Total Capital		 -147.32% 0.00% 25.94% -97,935.00% -337.33% -231.33% 2.17% 1.65% 3.69% -1.04% 0.00%
Short-Term Debt to Total Capital		 -0.63% 0.00% 0.00% -21,355.00% -201.44% -231.33% 2.17% 1.65% 3.69% -1.04% 0.00%
Long-Term Debt to Total Capital		 -146.69% 0.00% 25.94% -76,580.00% -135.90% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -1,784.39% 193.31% 287.41% -657,200.00% -1,341.39% -1,506.11% 2,163.92% 161.27% 273.45% -33.40% 14.70%
Common Equity to Total Capital		 2,031.71% -93.70% -214.12% 756,880.00% 1,778.72% 1,837.44% -2,066.08% -62.93% -177.14% 134.44% 85.30%
Debt to EBITDA		 -1.49 0.00 -0.20 -0.39 -0.82 -0.32 -0.01 -0.01 -0.01 -0.01 0.00
Net Debt to EBITDA		 -1.43 0.00 0.74 -0.10 -0.60 -0.10 1.06 1.27 0.70 0.35 0.00
Long-Term Debt to EBITDA		 -1.49 0.00 -0.20 -0.31 -0.33 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -1.79 0.00 -0.29 -0.55 -1.13 -0.42 -0.01 -0.02 -0.01 -0.01 0.00
Net Debt to NOPAT		 -1.71 0.00 1.05 -0.15 -0.83 -0.13 1.49 1.47 1.11 0.52 0.00
Long-Term Debt to NOPAT		 -1.78 0.00 -0.29 -0.43 -0.46 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 13.48 -3.81 -17.79 -44.59 -40.12 -22.16 -10.22 -11.41 -43.01 -10.89
Noncontrolling Interest Sharing Ratio		 -721.49% 2,626.62% 247.29% 2,128.34% -485.89% -351.46% -2,458.45% 572.48% 197.24% -178.68% -193.81%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.23 11.54 4.56 0.76 0.18 0.21 1.13 1.84 3.52 1.00 7.34
Quick Ratio		 0.20 11.40 4.50 0.73 0.09 0.13 0.92 1.59 3.18 0.90 7.08
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 5.84 -48 -34 -28 -21 -17 -9.40 -15 -9.98 -1.70 -22
Operating Cash Flow to CapEx		 0.00% -46,767.09% -58,083.13% -178,240.00% 0.00% 0.00% 0.00% 0.00% -76,295.24% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.97 -27.22 -85.63 -9.03 -6.51 -9.13 -13.58 -1,253.28 -665.00 -130.65 0.00
Operating Cash Flow to Interest Expense		 -5.12 -20.81 -121.13 -14.41 -8.16 -12.60 -26.01 -1,609.00 -1,068.13 -1,467.77 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -5.07 -20.86 -121.34 -14.42 -8.16 -12.47 -26.01 -1,609.00 -1,069.53 -1,467.77 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.12 0.01 0.01 0.01 0.68 0.31 0.53 0.20 0.07 0.00 0.04
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 78.70 37.26 17.55 0.00 12.40
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.41 0.24 1.19 0.80 70.45 10.41 15.49 12.42 8.32 0.00 14.03
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 4.64 9.80 20.80 0.00 29.43
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 4.64 9.80 20.80 0.00 29.43
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -26 -4.44 -8.88 -16 -8.89 -6.82 -5.72 -5.85 -12 -28 -22
Invested Capital Turnover		 -0.12 -0.03 -0.10 -0.02 -0.98 -0.35 -1.02 -0.69 -0.23 0.00 -0.04
Increase / (Decrease) in Invested Capital		 -26 22 -4.44 -7.55 7.54 2.06 1.10 -0.12 -5.80 -16 5.36
Enterprise Value (EV)		 0.00 297 241 334 182 144 209 92 68 27 9.40
Market Capitalization		 0.00 223 158 197 108 102 137 90 69 30 44
Book Value per Share		 $0.00 ($2.39) ($2.78) ($4.61) ($2.03) ($0.82) ($1.08) ($0.11) ($0.10) ($0.24) $3.82
Tangible Book Value per Share		 $0.00 ($2.39) ($2.78) ($4.61) ($2.03) ($0.82) ($1.08) ($0.11) ($0.10) ($0.24) $3.82
Total Capital		 -25 84 43 -0.02 -4.66 -2.67 3.88 15 6.06 -18 14
Total Debt		 36 0.00 11 20 16 6.17 0.08 0.26 0.22 0.19 0.00
Total Long-Term Debt		 36 0.00 11 15 6.33 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 35 -88 -40 5.19 12 1.92 -12 -22 -17 -9.26 -37
Capital Expenditures (CapEx)		 -0.30 0.08 0.08 0.03 -0.01 -0.24 0.00 0.00 0.02 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.61 -6.54 -11 -14 -7.66 -6.15 -4.84 -6.04 7.48 -9.22 -3.83
Debt-free Net Working Capital (DFNWC)		 -5.10 81 41 -2.30 -5.98 -4.37 0.91 7.38 20 0.23 33
Net Working Capital (NWC)		 -5.25 81 41 -6.57 -15 -11 0.83 7.12 19 0.04 33
Net Nonoperating Expense (NNE)		 16 14 17 19 9.97 7.31 4.51 2.57 9.30 8.11 5.78
Net Nonoperating Obligations (NNO)		 35 -88 -40 3.18 11 2.02 -9.52 -21 -17 -9.26 -37
Total Depreciation and Amortization (D&A)		 5.78 0.53 0.42 1.23 1.23 0.57 0.47 0.09 0.09 0.09 0.09
Debt-free, Cash-free Net Working Capital to Revenue		 -426.86% -1,260.69% -1,706.94% -4,885.22% -61.64% -222.43% -75.43% -150.71% 370.86% 0.00% -376.50%
Debt-free Net Working Capital to Revenue		 -329.12% 15,695.57% 6,416.88% -789.00% -48.10% -158.14% 14.17% 184.24% 971.75% 0.00% 3,236.68%
Net Working Capital to Revenue		 -339.12% 15,695.57% 6,416.88% -2,256.70% -123.56% -381.44% 12.86% 177.85% 960.65% 0.00% 3,236.68%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($27.60) ($23.60) ($7.20) ($8.40) ($10.40) ($9.71) ($3.20)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 820.31K 820.31K 820.31K 1.15M 1.63M 2.02M 2.25M 1.87M 2.08M 5.77M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($27.60) ($23.60) ($7.20) ($8.40) ($10.40) ($9.71) ($3.20)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 820.31K 820.31K 820.31K 1.15M 1.63M 2.02M 2.25M 1.87M 2.08M 5.77M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($27.60) ($23.60) ($7.20) ($8.40) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 820.31K 820.31K 820.31K 311.23K 757.30K 1.18M 1.52M 2.61M 3.01M 3.19M
Normalized Net Operating Profit after Tax (NOPAT)		 -20 -27 -39 -35 -14 -15 -8.30 -15 -16 -18 -17
Normalized NOPAT Margin		 -1,305.87% -5,144.39% -6,074.76% -12,191.55% -111.60% -529.10% -129.35% -378.61% -781.86% 0.00% -1,664.31%
Pre Tax Income Margin		 -2,330.60% -7,920.42% -8,730.76% -18,504.12% -190.16% -790.09% -199.59% -439.85% -1,232.56% 0.00% -2,222.71%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -4.99 -22.18 -138.30 -16.45 -6.21 -10.98 -17.52 -1,467.08 -1,680.67 -2,032.69 0.00
NOPAT to Interest Expense		 -3.36 -15.04 -96.77 -11.47 -4.22 -8.00 -11.99 -1,263.62 -1,051.87 -1,373.18 0.00
EBIT Less CapEx to Interest Expense		 -4.94 -22.23 -138.51 -16.46 -6.20 -10.85 -17.52 -1,467.08 -1,682.07 -2,032.69 0.00
NOPAT Less CapEx to Interest Expense		 -3.31 -15.09 -96.98 -11.48 -4.22 -7.87 -11.99 -1,263.62 -1,053.27 -1,373.18 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -6.93% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for vTv Therapeutics

This table displays calculated financial ratios and metrics derived from vTv Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
DEI Shares Outstanding		 104,577,460.00 104,577,460.00 3,010,206.00 3,010,206.00 3,010,206.00 3,189,606.00 3,189,606.00 3,194,564.00 3,194,564.00 3,938,259.00
DEI Adjusted Shares Outstanding		 2,614,437.00 2,614,437.00 3,010,206.00 3,010,206.00 3,010,206.00 3,189,606.00 3,189,606.00 3,194,564.00 3,194,564.00 3,938,259.00
DEI Earnings Per Adjusted Shares Outstanding		 -2.55 -1.33 -1.62 -1.72 -1.59 -1.14 -1.60 -1.89 -2.72 6.13
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -54.76% 27.59% -2.12% 5.45% 26.87% -7.67% -9.42% -10.28% -69.84% 456.28%
EBIT Growth		 -54.49% 27.49% -2.11% 5.43% 26.80% -7.61% -9.17% -9.95% -69.28% 455.77%
NOPAT Growth		 5.64% 25.79% 24.24% 10.56% -21.20% -3.93% -15.57% -7.91% -64.45% 611.04%
Net Income Growth		 -56.18% 27.08% -4.24% 11.12% 31.62% 0.09% -3.29% -15.15% -77.14% 488.19%
EPS Growth		 -56.18% 32.39% 45.83% 69.89% 72.41% 62.28% 34.19% -13.58% -22.73% 314.29%
Operating Cash Flow Growth		 45.24% 57.65% -41.99% -9.11% -32.77% -65.58% 22.47% 24.28% 18.64% 260.96%
Free Cash Flow Firm Growth		 90.11% 843.44% -131.46% -217.75% -168.75% -168.31% -209.34% -0.39% 53.51% 206.58%
Invested Capital Growth		 -123.87% -138.64% -4.54% 7.18% 11.27% 19.27% 15.63% 6.27% -16.80% 63.33%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% -100.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -17.80% 47.96% -32.83% -16.11% 8.89% 23.38% -34.99% -17.02% -40.32% 0.00%
EBIT Q/Q Growth		 -17.73% 47.83% -32.64% -16.07% 8.88% 23.30% -34.57% -16.91% -40.29% 0.00%
NOPAT Q/Q Growth		 32.90% 12.31% -19.55% -27.15% 9.07% 24.81% -32.93% -18.73% -38.57% 0.00%
Net Income Q/Q Growth		 -18.43% 48.00% -35.53% -6.48% 8.88% 24.02% -40.12% -18.71% -40.18% 0.00%
EPS Q/Q Growth		 -18.43% 47.65% 29.94% 30.77% -8.64% 28.41% -22.22% -19.48% -17.39% 0.00%
Operating Cash Flow Q/Q Growth		 21.62% 39.72% -151.72% 8.26% 4.62% 24.82% -17.87% 10.41% -2.49% 0.00%
Free Cash Flow Firm Q/Q Growth		 86.30% 16.94% -121.77% -148.29% -8.77% -16.19% 1.43% 19.42% 49.63% 0.00%
Invested Capital Q/Q Growth		 1.36% -4.28% 5.52% 4.49% 5.70% 5.13% 1.26% -6.11% -17.50% 0.00%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 100.00% 0.00% 0.00% 100.00% 0.00% 0.00% 0.00% 100.00%
EBITDA Margin		 0.00% 0.00% -597.60% 0.00% 0.00% -28,494.12% 0.00% 0.00% 0.00% 63.24%
Operating Margin		 0.00% 0.00% -562.70% 0.00% 0.00% -28,776.47% 0.00% 0.00% 0.00% 63.15%
EBIT Margin		 0.00% 0.00% -599.80% 0.00% 0.00% -28,623.53% 0.00% 0.00% 0.00% 63.24%
Profit (Net Income) Margin		 0.00% 0.00% -601.90% 0.00% 0.00% -26,100.00% 0.00% 0.00% 0.00% 65.51%
Tax Burden Percent		 100.00% 100.00% 101.69% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 98.53% 98.21% 98.68% 92.06% 92.06% 91.18% 94.95% 96.41% 96.33% 103.60%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 803.58% 408.59% -198.61% -362.13% -1,335.04% 1,068.97% -131.31% -209.04% -64.17% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% -14.45% 0.00% 0.00% -1,181.32% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% -14.50% 0.00% 0.00% -1,077.17% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 4,887.42% 1,138.66% -12.07% 227.30% 4,012.57% 3,140.74% -108.09% -176.05% -62.06% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 109.44% 0.00% -126.04% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.76 -3.29 -3.94 -5.01 -4.55 -3.42 -4.55 -5.40 -7.49 23
NOPAT Margin		 0.00% 0.00% -393.89% 0.00% 0.00% -20,143.53% 0.00% 0.00% 0.00% 63.15%
Net Nonoperating Expense Percent (NNEP)		 -30.17% -8.57% -5.35% -4.23% -4.79% -4.40% -4.00% -5.53% -4.09% 1.35%
Return On Investment Capital (ROIC_SIMPLE)		 - 13.45% -15.16% -24.51% -25.42% -23.95% -51.16% -224.73% -10.57% 25.86%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 397.80% 0.00% 0.00% 15,735.29% 0.00% 0.00% 0.00% 12.48%
R&D to Revenue		 0.00% 0.00% 264.90% 0.00% 0.00% 13,141.18% 0.00% 0.00% 0.00% 24.37%
Operating Expenses to Revenue		 0.00% 0.00% 662.70% 0.00% 0.00% 28,876.47% 0.00% 0.00% 0.00% 36.85%
Earnings before Interest and Taxes (EBIT)		 -8.67 -4.52 -6.00 -6.96 -6.34 -4.87 -6.55 -7.66 -11 23
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -8.65 -4.50 -5.98 -6.94 -6.32 -4.84 -6.54 -7.65 -11 23
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 3.41 3.23 2.72 3.61 6.98 17.35 1.06 1.74
Price to Tangible Book Value (P/TBV)		 0.00 0.00 3.41 3.23 2.72 3.61 6.98 17.35 1.06 1.74
Price to Revenue (P/Rev)		 5,554.23 0.00 70.83 53.16 40.83 43.31 3,249.65 2,818.73 4,387.83 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 5,395.34 0.00 23.77 11.60 2.17 9.24 1,480.12 1,272.91 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 -0.03 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 4.61 2.10 -2.95 -4.71 -15.79 10.83 -2.39 -3.13 -1.58 -1.31
Leverage Ratio		 -7.34 -3.48 3.15 4.91 17.07 -11.60 2.47 3.19 1.61 1.32
Compound Leverage Factor		 -7.23 -3.42 3.10 4.52 15.72 -10.58 2.35 3.08 1.55 1.37
Debt to Total Capital		 -3.37% -1.04% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.46% 0.00%
Short-Term Debt to Total Capital		 -3.37% -1.04% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.46% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -76.38% -33.40% 19.98% 19.39% 16.22% 14.70% 10.98% -14.84% 0.00% 0.00%
Common Equity to Total Capital		 179.75% 134.44% 80.02% 80.61% 83.78% 85.30% 89.02% 114.84% 99.54% 100.00%
Debt to EBITDA		 -0.02 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 0.00
Net Debt to EBITDA		 0.43 0.35 0.00 0.00 0.00 0.00 0.00 0.00 3.30 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.02 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 -0.02 0.00
Net Debt to NOPAT		 0.64 0.52 0.00 0.00 0.00 0.00 0.00 0.00 4.70 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -27.29 -36.45 -5.24 -7.01 -8.08 -9.22 -11.53 -15.26 -2.23 8.19
Noncontrolling Interest Sharing Ratio		 -508.21% -178.68% 93.92% 162.77% 400.56% -193.81% 17.68% 15.78% 3.28% 0.99%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.99 1.00 6.04 6.61 6.69 7.34 7.39 4.98 9.79 14.36
Quick Ratio		 0.80 0.90 5.97 6.56 6.51 7.08 7.20 4.90 9.69 14.25
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 11 13 -2.80 -6.95 -7.56 -8.78 -8.66 -6.98 -3.51 9.23
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 2,748.85 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -702.86 0.00
Operating Cash Flow to Interest Expense		 -1,208.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,044.40 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -1,208.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,044.40 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.02 0.03 0.03 0.04 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 12.40 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.05 0.00 7.14 8.55 10.53 14.03 0.30 0.39 0.53 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 29.43 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 29.43 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -27 -28 -26 -25 -24 -22 -22 -24 -28 -8.13
Invested Capital Turnover		 0.00 0.00 -0.04 -0.04 -0.04 -0.04 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -15 -16 -1.14 1.94 3.01 5.36 4.11 1.57 -3.98 14
Enterprise Value (EV)		 49 27 24 12 2.17 9.40 25 22 -24 58
Market Capitalization		 50 30 71 53 41 44 55 48 75 156
Book Value per Share		 ($0.24) ($0.24) $6.91 $5.47 $4.99 $3.82 $2.48 $0.86 $22.08 $7.25
Tangible Book Value per Share		 ($0.24) ($0.24) $6.91 $5.47 $4.99 $3.82 $2.48 $0.86 $22.08 $7.25
Total Capital		 -14 -18 26 20 18 14 8.90 2.41 71 90
Total Debt		 0.47 0.19 0.00 0.00 0.00 0.00 0.00 0.00 0.33 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -12 -9.26 -52 -46 -42 -37 -31 -26 -98 -98
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -7.92 -9.22 -7.30 -6.31 -5.04 -3.83 -3.46 -4.84 -8.88 -6.16
Debt-free Net Working Capital (DFNWC)		 0.32 0.23 45 39 37 33 28 21 90 92
Net Working Capital (NWC)		 -0.15 0.04 45 39 37 33 28 21 89 92
Net Nonoperating Expense (NNE)		 4.78 1.15 2.08 1.40 1.29 1.01 1.66 1.98 2.86 -0.87
Net Nonoperating Obligations (NNO)		 -12 -9.26 -52 -46 -42 -37 -31 -26 -98 -98
Total Depreciation and Amortization (D&A)		 0.02 0.02 0.02 0.02 0.02 0.02 0.01 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 -87,944.44% 0.00% -730.40% -631.10% -503.70% -376.50% -20,347.06% -28,488.24% -52,252.94% 0.00%
Debt-free Net Working Capital to Revenue		 3,588.89% 0.00% 4,495.10% 3,921.50% 3,653.40% 3,236.68% 162,352.94% 123,994.12% 527,182.35% 0.00%
Net Working Capital to Revenue		 -1,666.67% 0.00% 4,495.10% 3,921.50% 3,653.40% 3,236.68% 162,352.94% 123,994.12% 525,252.94% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($3.20) ($1.67) ($1.17) ($0.81) ($0.88) ($0.63) ($0.77) ($0.92) ($1.08) $1.94
Adjusted Weighted Average Basic Shares Outstanding		 2.04M 2.08M 4.14M 6.40M 5.46M 5.77M 6.58M 6.59M 8.06M 12.41M
Adjusted Diluted Earnings per Share		 ($3.20) ($1.67) ($1.17) ($0.81) ($0.88) ($0.63) ($0.77) ($0.92) ($1.08) $1.65
Adjusted Weighted Average Diluted Shares Outstanding		 2.04M 2.08M 4.14M 6.40M 5.46M 5.77M 6.58M 6.59M 8.06M 14.63M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($1.67) $0.00 $0.00 $0.00 ($0.63) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 2.61M 3.01M 3.01M 3.01M 3.19M 3.19M 3.19M 3.19M 3.94M 3.94M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.76 -3.29 -3.94 -5.01 -4.55 -3.42 -4.55 -5.40 -7.49 16
Normalized NOPAT Margin		 0.00% 0.00% -393.89% 0.00% 0.00% -20,143.53% 0.00% 0.00% 0.00% 44.20%
Pre Tax Income Margin		 0.00% 0.00% -591.90% 0.00% 0.00% -26,100.00% 0.00% 0.00% 0.00% 65.51%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -2,166.75 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2,147.80 0.00
NOPAT to Interest Expense		 -939.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,497.86 0.00
EBIT Less CapEx to Interest Expense		 -2,166.75 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2,147.80 0.00
NOPAT Less CapEx to Interest Expense		 -939.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,497.86 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

vTv Therapeutics (NASDAQ: VTVT) has shown a dramatic turnaround in its most recent quarter, but the bigger picture still reflects a company that is highly dependent on financing and milestone-style cash inflows. In Q1 2026, the company reported a large profit of $24.1 million, generated $9.2 million of operating cash flow, and ended the quarter with $98.1 million in cash and equivalents. That is a meaningful improvement from the prior year’s loss-making periods, but investors should note that the business still posted negative revenue in several earlier quarters and remains unprofitable on a multi-quarter basis.

  • Q1 2026 net income swung sharply positive to $24.1 million, versus a loss of $10.3 million in Q3 2025 and $7.4 million in Q2 2025.
  • Operating cash flow improved materially in Q1 2026 to $9.2 million, compared with negative operating cash flow in the prior several quarters.
  • Cash and equivalents rose to $98.1 million at March 31, 2026, giving the company a much stronger liquidity position than a year earlier.
  • Q1 2026 revenue of $36.8 million was a major step up from the zero-revenue quarters seen through much of 2024 and 2025.
  • Operating margin improved sharply in Q1 2026, with operating income of $23.3 million on $36.8 million of revenue.
  • Shares outstanding were lower in Q1 2026 than in some prior periods, which helped earnings per share look stronger.
  • Most of the balance sheet is still cash-heavy, with very limited noncash assets and little property, plant, and equipment.
  • Liabilities remain manageable in absolute terms at $8.9 million, but the company still carries a large accumulated deficit in retained earnings.
  • Prior quarters show heavy volatility in both earnings and cash generation, so one strong quarter may not indicate a stable trend yet.
  • vTv Therapeutics has a history of losses, including multiple quarters in 2024 and 2025 with operating losses between roughly $5 million and $11 million.
  • Revenue has been inconsistent, including several quarters with no operating revenue at all.
  • The company’s financing history is uneven, with prior quarters showing significant equity issuance and other financing activity, which can dilute existing shareholders.

Longer-term trend: The last four years show a business that has repeatedly burned cash and relied on outside financing, but the latest quarter stands out because it produced both revenue and positive operating cash flow. That combination is encouraging, yet investors should still view VTVT as a high-risk clinical or development-stage name until it can show that Q1 2026 was the start of a more durable operating trend.

07/26/26 12:27 PM ETAI Generated. May Contain Errors.

vTv Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, vTv Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

vTv Therapeutics' net income appears to be on a downward trend, with a most recent value of -$22.71 million in 2024, falling from -$36.10 million in 2014. The previous period was -$25.97 million in 2023. View vTv Therapeutics' forecast to see where analysts expect vTv Therapeutics to go next.

vTv Therapeutics' total operating income in 2024 was -$24.18 million, based on the following breakdown:
  • Total Gross Profit: $1.02 million
  • Total Operating Expenses: $25.20 million

Over the last 10 years, vTv Therapeutics' total revenue changed from $1.55 million in 2014 to $1.02 million in 2024, a change of -34.3%.

vTv Therapeutics' total liabilities were at $25.46 million at the end of 2025, a 6.2% increase from 2024, and a 219.4% increase since 2015.

In the past 10 years, vTv Therapeutics' cash and equivalents has ranged from $1.68 million in 2018 to $88.93 million in 2025, and is currently $88.93 million as of their latest financial filing in 2025.

Over the last 10 years, vTv Therapeutics' book value per share changed from 0.00 in 2014 to 3.82 in 2024, a change of 382.5%.


Related Companies

Financial statements for NASDAQ:VTVT last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The pact that ran the world and dollar just expired
In 1974, a U.S.-Saudi deal tied oil sales exclusively to dollars, forcing nations worldwide to hold dollars an...
Golden Portfolio | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
Universal basic income is not impossible. It exist (kind of)
Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...
Freedom Financial | Sponsoredtc pixel
I don't usually write you like this
Behind the Markets editor Kelly Maguire says she has never sent an email quite like this one. A sealed congres...
Behind the Markets | Sponsoredtc pixel
The invention Elon called the greatest in history
Jeff Brown and Marc Chaikin - two investors who called Nvidia a decade ago - say Elon Musk's newly filed AI pa...
Brownstone Research | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel